Table 2 General characteristics, pulmonary function test, peak VO2 and peak load of patients included in the two cohorts: *Cardiovascular comorbidity defined as the presence of coronary heart disease, cerebrovascular disease or peripheral arterial disease.
From: An objective method to detect sighs during cardio-pulmonary exercise testing
Derivation cohort | Validation cohort | |
|---|---|---|
Overall population | 48 | 79 |
Demographics | ||
Age, years, mean (SD) | 49 (15) | 51 (12) |
Women, n (%) | 33 (69) | 45 (57) |
BMI, kg/m2, mean (SD) | 26.6 (4.6) | 28.4 (6.4) |
Coexisting conditions, n (%) | ||
Cardiovascular comorbidity*, n (%) | 3 (6) | 14 (18) |
Diabetes mellitus | 2 (4) | 3 (4) |
Hypertension | 7 (15) | 14 (18) |
Obesity | 11 (23) | 31 (39) |
History of asthma | 7 (15) | 9 (11) |
Smoking status n (%) | ||
Never | 33 (69) | 72 (91) |
Current | 2 (4) | 3 (4) |
Former | 13 (27) | 4 (5) |
Hospitalisation, yes, n (%) | 7 (14.6) | 37 (49) |
Pulmonary function tests | ||
FVC (% of predicted value) | 101 (12.0) | 93 (14.8) |
FEV1 (% of predicted value) | 100 (16.8) | 95 (11.1) |
FEV1/FVC (< -1.64 Z score) | 0 (0%) | 2 (3%) |
TLCO (% predicted value) | 90 (13.2) | 84 (20) |
Cardiopulmomary exercise test | ||
VO2 peak (% of predicted value) | 85% (20.5) | 81% (19.3) |
Peak load (% of predicted value) | 90% (25) | 93% (25.9) |
